List view / Grid view
27 April 2015 | By Victoria White
Stealth BioTherapeutics has expanded its ophthalmology programme, led by Ocuvia, with FDA granting a Type B meeting for inherited optic neuropathies...
27 April 2015 | By Victoria White
NanoViricides has discussed the significance of the effectiveness demonstrated by its anti-viral drug candidates in a lethal animal model of dermal herpes...
27 April 2015 | By Victoria White
Preclinical data from Synthetic Biologics’ novel SYN-005 programme for the treatment of Pertussis were presented in two posters at ECCMID 2015...
24 April 2015 | By Victoria White
arGEN-X and de Duve Institute/UCL/WELBIO have announced the publication of new data showing that ARGX-115 blocks the activity of GARP...
24 April 2015 | By Victoria White
AstraZeneca and Celgene collaborate for the development and commercialisation of MEDI4736 across a range of blood cancers, including non-Hodgkin’s lymphoma...
24 April 2015 | By Victoria White
New preclinical data demonstrates that BLU-554 has significant anti-tumour activity in models of HCC that are dependent on FGFR4 signalling...
23 April 2015 | By Victoria White
MRC Technology and NYU School of Medicine have signed an agreement to develop an antibody for the prevention of inflammatory osteolysis (bone breakdown)...
23 April 2015 | By Victoria White
Bayer and UKE are the main coordinators of a new international consortium, CANCER-ID, to develop novel blood-based biomarker technologies in cancer...
23 April 2015 | By Victoria White
Cytori Therapeutics presented data from two preclinical studies at ABA2015. The findings provide greater detail on Cytori's cell therapies...
23 April 2015 | By Victoria White
Dimension Therapeutics is advancing programmes to treat two rare diseases with often devastating outcomes for patients - OTC deficiency and GSDIa...
23 April 2015 | By Victoria White
An article describing an important scientific foundation for the clinical development of truly personalised cancer immunotherapies has been published...
22 April 2015 | By Victoria White
New preclinical data demonstrates that mAbXcite therapies causes an immune cascade that successfully recruits T-cells to mount an attack against cancer...
22 April 2015 | By Victoria White
Blend Therapeutics has presented preclinical data on it's lead product candidate, BTP-114, a novel personalised cisplatin prodrug, at AACR 2015...
22 April 2015 | By Victoria White
ARIAD has announced the results of a series of preclinical studies on its investigational tyrosine kinase inhibitor, brigatinib (AP26113), at AACR 2015...
22 April 2015 | By Victoria White
Astellas and Potenza have entered an exclusive R&D collaboration. The agreement includes an option for the future acquisition of Potenza by Astellas...
